Unlocking the potential of
genomic medicine


Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.  More>>

There are no items to display.

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary01/02/2019
PHILADELPHIA , Jan. 2, 2019 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) ("the Company") today announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 – 400 mg BID) in children aged 6 – 17 with
Toggle Summary11/26/2018
PHILADELPHIA , Nov. 26, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc.  (NASDAQ: GNMX) (the Company) announced today that the Aevi Genomic Medicine Management team will host a breakfast with Key Opinion Leader (KOL) Robert Findling, M.D., Leonard and Helen R.
Toggle Summary11/01/2018
PHILADELPHIA , Nov. 1, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") announced today financial and operational results for the three months ended September 30 , 2018 and provided an overview of the Company's recent corporate progress.

Recent Presentations

More >>
Date Title

Upcoming Events

More >>
There are currently no events to display.

Recent Events

More >>
Date Event Details
Summary Toggle 11/29/18 at 8:00 AM EST

Aevi Genomic Medicine KOL Breakfast to Discuss Diagnosis and Treatment Paradigms in ADHD

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Aevi Genomic Medicine, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Copyright West LLC. Minimum 15 minutes delayed.